Atorwastatyna jako wybór u pacjentów z zaburzeniami funkcji nerek Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2015
Słowa kluczowe:
przewlekła choroba nerek, statyny, powikłania sercowo-naczyniowe, atorwastatyna
##plugins.themes.bootstrap3.article.main##
Abstrakt
Choroby układu sercowo-naczyniowego są poważnym problemem w grupie pacjentów z przewlekłą chorobą nerek (PChN), a częstość ich występowania jest szczególnie wysoka w schyłkowej niewydolności nerek. Według najnowszych wytycznych zdecydowana większość pacjentów z postępującą PChN kwalifikuje się do leczenia statynami, które w świetle dostępnych badań zmniejszają ryzyko zdarzeń sercowo-naczyniowych w tej grupie. Zaleca się ich stosowanie niezależnie od stadium PChN, w tym u osób leczonych nerkozastępczo. Atorwastatynę należy traktować jako lek pierwszego wyboru w związku z wykazanym efektem nefroprotekcyjnym. Niestety w praktyce klinicznej nadal powszechna jest zasada, że wysokie dawki statyn w zaawansowanej PChN należy przepisywać bardzo ostrożnie. Zmiana tego przekonania prawdopodobnie będzie możliwa dopiero po przeprowadzeniu prospektywnych randomizowanych badań na dużej grupie chorych.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Pawlaczyk, K., Schwermer, K., Hoppe, K., & Bręborowicz, P. (2015). Atorwastatyna jako wybór u pacjentów z zaburzeniami funkcji nerek . Medycyna Faktów , 8(4(29), 50-53. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2282
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Baigent C., Landray M.J., Reith C. et al.; SHARP Investigators: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377(9784): 2181-2192.
2. Cholesterol Treatment Trialists’ (CTT) Collaboration; Baigent C., Blackwell L., Emberson J. et al.: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376(9753): 1670-1681.
3. Sever P.S., Dahlöf B., Poulter N.R. et al.; ASCOT Investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361(9364): 1149-1158.
4. Colantonio L.D., Baber U., Banach M. et al.: Contrasting Cholesterol Management Guidelines for Adults with CKD. J. Am. Soc. Nephrol. 2015; 26(5): 1173-1180.
5. Wanner C., Tonelli M.; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group: KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014; 85(6): 1303-1309.
6. Tonelli M., Wanner C.; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members: Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. Ann. Intern. Med. 2014; 160(3): 182.
7. de Zeeuw D., Anzalone D.A., Cain V.A. et al.: Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol. 2015; 3(3): 181-190.
8. Jacobson T.A.: Statin safety: lessons from new drug applications for marketed statins. Am. J. Cardiol. 2006; 97(8A): 44C-51C.
9. Sidaway J.E., Davidson R.G., McTaggart F. et al.: Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J. Am. Soc. Nephrol. 2004; 15(9): 2258-2265.
10. Moorhead J.F., Chan M.K., El-Nahas M., Varghese Z.: Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982; 2(8311): 1309-1311.
11. Hou W., Lv J., Perkovic V. et al.: Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur. Heart J. 2013; 34(24): 1807-1817.
12. Ray K.K., Cannon C.P., McCabe C.H. et al.; PROVE IT-TIMI 22 Investigators: Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J. Am. Coll. Cardiol. 2005; 46(8): 1405-1410.
13. Wong M.G., Wanner C., Knight J., Perkovic V.: Lowering cholesterol in chronic kidney disease: is it safe and effective? Eur. Heart J. 2015: ehv393.
14. Ridker P.M., Danielson E., Fonseca F.A. et al.; JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 2008; 359(21): 2195-2207.
15. Zewinger S., Speer T., Kleber M.E. et al.: HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction. J. Am. Soc. Nephrol. 2014; 25(5): 1073-1082.
2. Cholesterol Treatment Trialists’ (CTT) Collaboration; Baigent C., Blackwell L., Emberson J. et al.: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376(9753): 1670-1681.
3. Sever P.S., Dahlöf B., Poulter N.R. et al.; ASCOT Investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361(9364): 1149-1158.
4. Colantonio L.D., Baber U., Banach M. et al.: Contrasting Cholesterol Management Guidelines for Adults with CKD. J. Am. Soc. Nephrol. 2015; 26(5): 1173-1180.
5. Wanner C., Tonelli M.; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group: KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014; 85(6): 1303-1309.
6. Tonelli M., Wanner C.; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members: Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. Ann. Intern. Med. 2014; 160(3): 182.
7. de Zeeuw D., Anzalone D.A., Cain V.A. et al.: Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol. 2015; 3(3): 181-190.
8. Jacobson T.A.: Statin safety: lessons from new drug applications for marketed statins. Am. J. Cardiol. 2006; 97(8A): 44C-51C.
9. Sidaway J.E., Davidson R.G., McTaggart F. et al.: Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J. Am. Soc. Nephrol. 2004; 15(9): 2258-2265.
10. Moorhead J.F., Chan M.K., El-Nahas M., Varghese Z.: Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982; 2(8311): 1309-1311.
11. Hou W., Lv J., Perkovic V. et al.: Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur. Heart J. 2013; 34(24): 1807-1817.
12. Ray K.K., Cannon C.P., McCabe C.H. et al.; PROVE IT-TIMI 22 Investigators: Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J. Am. Coll. Cardiol. 2005; 46(8): 1405-1410.
13. Wong M.G., Wanner C., Knight J., Perkovic V.: Lowering cholesterol in chronic kidney disease: is it safe and effective? Eur. Heart J. 2015: ehv393.
14. Ridker P.M., Danielson E., Fonseca F.A. et al.; JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 2008; 359(21): 2195-2207.
15. Zewinger S., Speer T., Kleber M.E. et al.: HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction. J. Am. Soc. Nephrol. 2014; 25(5): 1073-1082.